Man Group
ABUS icon

Man Group’s Arbutus Biopharma ABUS Stock Holding History

Man Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27M Buy
+473,467
New +$2.08M ﹤0.01% 1512
2026
Q1 		– Sell
-120,821
Closed -$581K – 2368
2025
Q4 		$581K Buy
120,821
+41,447
+52% +$186K ﹤0.01% 1850
2025
Q3 		$360K Buy
79,374
+40,377
+104% +$148K ﹤0.01% 1950
2025
Q2 		$121K Buy
+38,997
New +$129K ﹤0.01% 2113
2023
Q3 		– Sell
-24,500
Closed -$56.4K – 1898
2023
Q2 		$56.4K Buy
+24,500
New +$63.8K ﹤0.01% 1910
2023
Q1 		– Sell
-44,900
Closed -$105K – 2055
2022
Q4 		$105K Sell
44,900
-42,346
-49% -$101K ﹤0.01% 1904
2022
Q3 		$167K Buy
+87,246
New +$205K ﹤0.01% 1796

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Man Group's ABUS Position: Q2 2026 in Review

Man Group opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 473,467 shares worth $2.27M. The stake represents ﹤0.01% of the portfolio and ranks #1512 among its holdings. This is a return to the name: Man Group previously reported a position in ABUS as recently as Q4 2025.

Man Group first reported a position in ABUS in Q3 2022 and has held it in 7 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Man Group held 473,467 shares of Arbutus Biopharma worth $2.27M as of Q2 2026.
  • Arbutus Biopharma was a new Man Group position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1512 holding.
  • Man Group first reported a position in Arbutus Biopharma in Q3 2022 and has held it in 7 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.